title: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.
abstract: We have previously observed a positive correlation between Plasminogen Activator Inhibition capacity (PA Inhibition), Body Mass Index (BMI) and plasma insulin levels in a population of non diabetic subjects. The anti diabetic biguanide Metformin which decreases insulin resistance has been reported to increase the blood fibrinolytic activity. Therefore we have studied the effect of Metformin on PA Inhibition levels in obese subjects with normal glucose tolerance. Eighteen obese women (O) (BMI: 31.4 +/- 1.13, m +/- S.E.M.) were compared to age matched controls (C) (BMI: 20.2 +/- 0.8) and randomized to a 15 days treatment by Metformin (M) (1.7 g/day) or placebo (P) in a double blind study while on a weight maintaining diet. O compared to C had higher levels (m +/- S.E.M.) of PA Inhibition (9 +/- 1.8 IU/ml, versus 2.88 +/- 0.29 p less than 0.01), lower euglobulin fibrinolytic activity (EFA) (4.95 +/- 1.17 mm versus 9 +/- 0.29 p less than 0.05), higher plasma insulin (24.1 +/- 2.1. uU/ml), versus 12 +/- 1 p less than 0.01) and triglyceride (1.32 +/- 0.16 mmol/l, versus 0.8 +/- 0.08 p less than 0.05). After 15 days of treatment, in group M a significant decrease in PA Inhibition (5.51 +/- 1.4, versus 9.48 +/- 2.1 p less than 0.05) in plasma insulin (18.5 +/- 0.1, versus 24.5 +/- 3.5, p less than 0.05) and plasma triglyceride (1.08 +/- 0.1, versus 1.47 +/- 0.3 p less than 0.05) and an increase in EFA (6.50 +/- 0.28, versus 5.25 +/- 0.35 p less than 0.05) were observed. No significant variation was observed in group P.
authors.affiliation: Service de Médecine Interne et Nutrition Hôpital Michel Levy, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Vague
authors.forename: I
authors.initials: I
authors.lastname: Juhan-Vague
authors.forename: M C
authors.initials: MC
authors.lastname: Alessi
authors.forename: C
authors.initials: C
authors.lastname: Badier
authors.forename: J
authors.initials: J
authors.lastname: Valadier
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood*; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D015849:Plasminogen Inactivators; D012016:Reference Values; D014280:Triglycerides / Q000097:blood*
chemical_list: D001786:Blood Glucose; D006023:Glycoproteins; D007328:Insulin; D015849:Plasminogen Inactivators; D014280:Triglycerides; D008687:Metformin